Innovent Doses First Participant in Pivotal Phase 3 Clinical Trial for IBI354 Targeting HER2-Positive Breast Cancer #China #Suzhou #HER2-positive #Innovent #IBI354
0
0
0
0
Innovent Doses First Participant in Pivotal Phase 3 Clinical Trial for IBI354 Targeting HER2-Positive Breast Cancer #China #Suzhou #HER2-positive #Innovent #IBI354